Effects of treatment with Glucagon‐like peptide‐1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta‐analysis
Weihao Wang, Ran Wei, Zhengxiang Huang, Jingyi Luo, Qi Pan, Lixin Guo
Abstract
Abstract Objective This study aimed to evaluate the effects of Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) on prediabetes with overweight/ obesity. Methods A search of PubMed, Embase, Cochrane Library, and Web of Science databases was performed to identify randomised controlled trials (up to 4 July 2022) which evaluated the effect of GLP‐1RA on prediabetes with overweight/ obesity. Results Eight hundred and nine articles were retrieved (80 from PubMed, 481 from Embase, 137 from Cochrane library, and 111 from Web of Science) and a total of 5 articles were included in this meta‐analysis. More individuals in GLP‐1RAs group regressed from prediabetes to normoglycemia than individuals in the placebo group (OR = 4.56, 95% CI:3.58, 5.80, P = 0.004); fewer individuals in GLP‐1RAs group were diagnosed with diabetes than those in the placebo group (OR = 0.31, 95% CI:0.12,0.81, P = 0.017). Results from five studies showed that GLP‐1RAs significantly reduced fasting glucose (mean difference = −0.41 mmol/L, 95% CI: −0.58, −0.25, P < 0.00001), with an acceptable heterogeneity (I 2 = 42%). Conclusions The present meta‐analysis suggested that GLP‐1RA significantly improves glucose metabolism, reduces systolic blood pressure and body weight in prediabetes with overweight/ obesity. It could also prevent the development of diabetes and reverse abnormal glucose metabolism.